Randomized Controlled Trial of Cilostazol Addition for In-Stent Restenosis After Carotid Artery Stenting
Background
Restenosis, or narrowing of the arteries, after carotid artery stenting (CAS) can increase the risk of ischemic stroke. This study looked at whether adding cilostazol to treatment could reduce this risk.
Methods
In this trial, patients with carotid artery issues scheduled for CAS were randomly assigned to either receive cilostazol (50 or 100 mg, twice daily) along with other antiplatelet medications or to receive only the antiplatelet medications. The study monitored the incidence of restenosis over two years using ultrasound to measure blood flow.
Results
From December 2010 to September 2015, 631 patients were analyzed. Results showed:
- In the cilostazol group, 31 out of 325 patients (10.8%) had restenosis.
- In the non-cilostazol group, 46 out of 306 patients (19.6%) had restenosis.
- This indicates a lower risk for those who received cilostazol (hazard ratio 0.64).
- Beyond 30 days, the cilostazol group showed a further reduced incidence of restenosis (10.3% vs. 19.3%).
- Similar rates of cardiovascular events and bleeding were observed in both groups.
Conclusions
Adding cilostazol to antiplatelet therapy may help reduce the risk of restenosis after CAS. Further studies are needed to confirm these findings.
Registration
For more details, visit ClinicalTrials.gov; Unique identifier: NCT01261234.
Value of Clinical Trials
Clinical trials are essential for developing new and effective treatments. Our AI-driven platform, DocSym, makes it easier for healthcare providers to access standardized clinical protocols and research.
Practical Solutions
- Streamline healthcare operations with our mobile apps for scheduling and telemedicine.
- Reduce paperwork and enhance patient care through AI integration.
Learn more about how we can assist at aidevmd.com.
